Explore Stanford technologies available for licensing:

Melanoma is responsible for a disproportionate number of cancer deaths, with few effective treatment options for patients with advanced disease.

Disease indication - Cancer, specifically:
-highly mutated cancers, including the ~20% of cancer with BAF complex mutations
-combination therapy with ATR inhibitors

Disease Indication: Pain relief

Drug Format: Small molecule

Drug Class: First in class

Research Stage: In vitro/Lead selection

Target: CB1R

Stanford researchers have demonstrated the application of pulsed Focused Ultrasound (pFUS), to non-invasively enhance the function and engraftment of pancreatic islets following transplantation.

Researchers in Prof. A.C. Matin's laboratory have developed a versatile exosome (extracellular vesicle, "EV") drug delivery platform that can selectively target therapeutic agents to tumors or other tissues that overexpress extracellular receptors.

Researchers at Stanford have developed agents to enhance the therapeutic efficacy of a variety of anti-cancer therapeutics. Cell loss by apoptosis occurs in normal development and in tumor environments.

Stanford researchers have developed a rapid, accurate, and accessible method to test for food allergy and other types of allergy.

Disease Indication Oncology, hematological cancers, breast cancer, solid tumors

Drug Format Cell therapy

Drug Class Best-in-class

Target CD19, HER2, B7-H3, GPC2 and all other tumor antigens

Researchers in Dr. Mark Kay's lab have developed a patented approach to inducing apoptosis that could represent a new strategy against cancer and other diseases.

This bandage-like multi-lead, continuous ECG monitoring device uses new stretchable electrode material developed in the Bao group to accurately and imperceptibly diagnose cardiac arrhythmia.

Researchers at Stanford have developed a device capable of delivering ultrasonic neuromodulation to defined areas of the brain while simultaneously recording neuronal activity with cell-type specificity.

Stanford researchers at the Prakash Lab have developed Octopi, a low-cost ($250-$500) and reconfigurable autonomous microscopy platform capable of automated slide scanning and correlated bright-field and fluorescence imaging.

Researchers at Stanford have developed a novel therapeutic approach for dilated cardiomyopathy (DCM). DCM is characterized by left ventricular enlargement and reduced systolic function.

Researchers at Stanford and their colleagues have developed new antibiotic compounds that could be used to treat staph infection (caused by Staphylococcus aureus) and TB infection (caused by Mycobacterium tuberculosis).

Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have developed a method for treating and predicting treatment efficacy of triple negative breast cancer (TNBC).